Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases

Authors:

Abstract
Although the additional benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) has been debated,1,2 CRS-HIPEC has been recommended for selected patients with resectable colorectal peritoneal metastases (CPM) in most national and international guidelines.3 Addition of perioperative (ie, neoadjuvant and adjuvant) systemic therapy to CRS-HIPEC may improve oncologic outcomes by preoperative tumor downstaging, eradication of systemic micrometastases, and postoperative elimination of microscopic residual disease. However, perioperative systemic therapy could induce toxic effects; may increase postoperative morbidity, especially when including bevacizumab4; and could result in preoperative intraperitoneal progression and consequent inoperability given its assumed relative inefficacy for CPM.5 To our knowledge, there have been no randomized trials investigating the value of perioperative systemic therapy for resectable CPM,6,7 leading to a wide variety in its administration and timing among countries and hospitals.3,6,8 To address this evidence gap, the CAIRO6 trial has been designed to assess whether perioperative systemic therapy improves overall survival of patients diagnosed with resectable CPM relative to CRS-HIPEC alone, the latter being standard of care in the Netherlands.9 Because CAIRO6 appears to be the first randomized trial investigating perioperative systemic therapy in this setting, a randomized phase 2 trial, reported herein, was incorporated to assess the feasibility and safety of perioperative systemic therapy, the response of CPM to neoadjuvant treatment, and the trial’s accrual before proceeding to a phase 3 trial.

This publication has 34 references indexed in Scilit: